I am a
Home I AM A Search Login

Papers of the Week

2022 Nov 22


Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.


Ozdarendeli A, Sezer Z, Pavel S T I, Inal A, Yetiskin H, Kaplan B, Uygut M A, Bayram A, Mazicioglu M, Unuvar G K, Yuce Z T, Aydin G, Aslan A F, Kaya R K, Koc R C, Ates I, Kara A
Vaccine. 2022 Nov 22.
PMID: 36460536.


Development of safe and effective vaccine options is crucial to the success of fight against COVID-19 pandemic. Herein, we report interim safety and immunogenicity findings of the phase 1&2 trials of ERUCoV-VAC, an inactivated whole virion SARS-CoV-2 vaccine.